Core Viewpoint - The approval of non-naloxone by the National Medical Products Administration of China marks a significant milestone for the company, as it becomes the second domestic enterprise to receive such approval for this active pharmaceutical ingredient [1] Group 1: Company Developments - The company, Shijiazhuang Fourth Pharmaceutical Group, has announced that its non-naloxone has been approved for registration as an active pharmaceutical ingredient for use in marketed formulations [1] - This approval positions the company as a key player in the market for treatments related to chronic kidney disease associated with type 2 diabetes [1] Group 2: Product Significance - Non-naloxone is primarily used for adult patients with chronic kidney disease related to type 2 diabetes, and it is effective in reducing the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage renal disease, cardiovascular mortality, and hospitalization due to heart failure [1]
石四药集团(02005)：非奈利酮已获国家药品监督管理局批准登记成为在上市制剂使用的原料药